We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
As we make our way to the end of the year, top money managers and investors of all types will begin to go away for the holiday season and focus their time on family and relaxation rather than the stock market. Today’s CPI number and Wednesday’s FOMC decision will likely facilitate higher volumes and some market movement. However, volumes will probably dry up as we enter the end-of-year doldrums. Nevertheless, catalyst-driven moves such as earnings reports, analyst movements, and surprise company-specific headlines are worth monitoring. Below, we will cover 5 of the top headline-driven moves.
1.) Boeing (BA): Shares of the leading aerospace company rose by nearly 4% after a positive analyst note from JP Morgan (JPM - Free Report) . JPM raised their outlook on the airplane maker to “overweight” and cited catalysts including the return of production of the 787 and the re-certification of the troubled 737 Max in China, the largest airplane market in the world.
2.) Rivian Automotive (RIVN - Free Report) : Monday, the Amazon (AMZN - Free Report) backed electric car start-up slid 6% to more than 6-month lows on news that the company would be scrapping plans to pursue a joint venture with German luxury car maker Mercedes Benz. Ceo RJ Scaringe cited in a statement that “We pursue the best risk-adjusted returns based on our capital”. Rivian has yet to post a profit as a public company and sports a mediocre Zacks Ranking of 3. Shares rebounded on Tuesday after the surprise drop in CPI data was announced.
3.) Oracle (ORCL - Free Report) : Database software giant Oracle reported earnings of $1.21 per share, outpacing the Zacks Consensus Estimates of $1.17 per share. Shares gained 1.78% Monday and were up more than 4% early in Tuesday’s session. Oracle shares have been on the mend in recent weeks. Earlier in the month, Oracle, Amazon, Microsoft (MSFT - Free Report) , and Alphabet (GOOGL - Free Report) won a piece of a pentagon contract totaling an estimated $9 billion. The technical picture for ORCL shows that the 50-day moving average is crossing over the 200-day moving average in what is known as a “Golden Cross”, a bullish sign for shares.
Image Source: Zacks Investment Research
Pictured: AMGN's 50-day crosses over its 200-day to form a "Golden Cross" pattern.
Software stocks were already strong after news broke that private equity firm Thoma Bravo will take Coupa Software private in a deal worth over $6 billion. Elsewhere in software, shares of Box Inc (BOX - Free Report) launched higher after an upgrade, while Nutanix (NTNX - Free Report) worked on its 8th straight week in the green.
4.) Horizon Therapeutics (HZNP): Amgen (AMGN - Free Report) acquired shares of Horizon Therapeutics in a $27.8 billion mega-deal announced and hammered out over the weekend. Shares of Horizon jumped 15% on the news. Amgen has a Zacks Rank of 3 however, the company has been performing well as of late and is highly profitable. AMGN pulled back slightly on the news and is testing its rising 50-day moving average, a dip buying zone often used by intermediate traders.
Image Source: Zacks Investment Research
Pictured: AMGN is looking to get support at its rising 50-day moving average - a key level for intermiediate speculators.
5.) Moderna (MRNA - Free Report) : The therapeutic and vaccine maker saw shares rise by nearly 20% early Tuesday after news broke that Moderna’s mRNA vaccine for melanoma reduced death and recurrence of disease in a Phase 2 trial. Moderna’s drug is taken in combination with Merck’s (MRK - Free Report) Keytruda drug. Shares of MRK were little changed. Moderna’s stock is rebounding from an initial slowdown after enjoying windfall profits from its Covid 19 vaccine. The stock found clear support at its 50-day moving average as volume traded above the 50-day average just minutes into the session.
Image Source: Zacks Investment Research
Pictured: Though Moderna's estimates and stock have retreated, today's news may be the catalyst it needs to get back on track.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Trending Today: 5 Stocks in the News
As we make our way to the end of the year, top money managers and investors of all types will begin to go away for the holiday season and focus their time on family and relaxation rather than the stock market. Today’s CPI number and Wednesday’s FOMC decision will likely facilitate higher volumes and some market movement. However, volumes will probably dry up as we enter the end-of-year doldrums. Nevertheless, catalyst-driven moves such as earnings reports, analyst movements, and surprise company-specific headlines are worth monitoring. Below, we will cover 5 of the top headline-driven moves.
1.) Boeing (BA): Shares of the leading aerospace company rose by nearly 4% after a positive analyst note from JP Morgan (JPM - Free Report) . JPM raised their outlook on the airplane maker to “overweight” and cited catalysts including the return of production of the 787 and the re-certification of the troubled 737 Max in China, the largest airplane market in the world.
2.) Rivian Automotive (RIVN - Free Report) : Monday, the Amazon (AMZN - Free Report) backed electric car start-up slid 6% to more than 6-month lows on news that the company would be scrapping plans to pursue a joint venture with German luxury car maker Mercedes Benz. Ceo RJ Scaringe cited in a statement that “We pursue the best risk-adjusted returns based on our capital”. Rivian has yet to post a profit as a public company and sports a mediocre Zacks Ranking of 3. Shares rebounded on Tuesday after the surprise drop in CPI data was announced.
3.) Oracle (ORCL - Free Report) : Database software giant Oracle reported earnings of $1.21 per share, outpacing the Zacks Consensus Estimates of $1.17 per share. Shares gained 1.78% Monday and were up more than 4% early in Tuesday’s session. Oracle shares have been on the mend in recent weeks. Earlier in the month, Oracle, Amazon, Microsoft (MSFT - Free Report) , and Alphabet (GOOGL - Free Report) won a piece of a pentagon contract totaling an estimated $9 billion. The technical picture for ORCL shows that the 50-day moving average is crossing over the 200-day moving average in what is known as a “Golden Cross”, a bullish sign for shares.
Image Source: Zacks Investment Research
Pictured: AMGN's 50-day crosses over its 200-day to form a "Golden Cross" pattern.
Software stocks were already strong after news broke that private equity firm Thoma Bravo will take Coupa Software private in a deal worth over $6 billion. Elsewhere in software, shares of Box Inc (BOX - Free Report) launched higher after an upgrade, while Nutanix (NTNX - Free Report) worked on its 8th straight week in the green.
4.) Horizon Therapeutics (HZNP): Amgen (AMGN - Free Report) acquired shares of Horizon Therapeutics in a $27.8 billion mega-deal announced and hammered out over the weekend. Shares of Horizon jumped 15% on the news. Amgen has a Zacks Rank of 3 however, the company has been performing well as of late and is highly profitable. AMGN pulled back slightly on the news and is testing its rising 50-day moving average, a dip buying zone often used by intermediate traders.
Image Source: Zacks Investment Research
Pictured: AMGN is looking to get support at its rising 50-day moving average - a key level for intermiediate speculators.
5.) Moderna (MRNA - Free Report) : The therapeutic and vaccine maker saw shares rise by nearly 20% early Tuesday after news broke that Moderna’s mRNA vaccine for melanoma reduced death and recurrence of disease in a Phase 2 trial. Moderna’s drug is taken in combination with Merck’s (MRK - Free Report) Keytruda drug. Shares of MRK were little changed. Moderna’s stock is rebounding from an initial slowdown after enjoying windfall profits from its Covid 19 vaccine. The stock found clear support at its 50-day moving average as volume traded above the 50-day average just minutes into the session.
Image Source: Zacks Investment Research
Pictured: Though Moderna's estimates and stock have retreated, today's news may be the catalyst it needs to get back on track.